Project 3: The Role of Macrophages in Resistance to Anti-VEGF Drugs in Ovarian Cancer

项目3:巨噬细胞在卵巢癌抗VEGF药物耐药中的作用

基本信息

  • 批准号:
    10251116
  • 负责人:
  • 金额:
    $ 34.45万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-22 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

Project 3 SUMMARY/ABSTRACT Angiogenesis is known to play a critical role in cancer growth and metastasis. Among the many potential targets, vascular endothelial growth factor (VEGF) has been well recognized to play an important role in angiogenesis, and drugs targeting this pathway have been used against ovarian and other cancers. Clinical use of anti-VEGF therapy, however, has yielded only modest improvement in progression-free or overall survival of patients with ovarian cancer, likely due to adaptive changes in the tumor microenvironment. There remains an unmet need to develop methods to enhance efficacy of anti-VEGF therapy and block growth- promoting adaptive changes. The mechanisms of adaptive resistance to anti-VEGF treatment are largely unknown. Understanding the adaptive resistance to anti-VEGF treatment has the potential to significantly enhance the efficacy of anti-VEGF therapy in ovarian cancer patients. Our preliminary findings suggest that tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) are substantially increased in the anti-VEGF therapy-resistant tumors and TAM depletion (with CSF1R inhibitor) can improve the effectiveness of anti-VEGF therapy; however, the mechanisms by which this occurs are not well understood. In this proposal, we will explore the mechanisms by which macrophages contribute to adaptive resistance to anti-VEGF treatment and test the efficacy of dual targeting of VEGF and TAMs/MDSCs. Our central hypothesis is that targeting TAMs in the microenvironment will reverse the immunophenotypical alterations induced by bevacizumab and improve clinical efficacy. We will conduct a novel, induction, randomized supplementation clinical study to assess the impact of adding a CSF1R inhibitor to identify and overcome these effects as measured by objective response and event-free survival. The proposed work is highly translational and has the potential to significantly enhance the efficacy of anti-VEGF therapy in ovarian cancer patients.
项目3概要/摘要 已知血管生成在癌症生长和转移中起关键作用。在众多潜在的 血管内皮生长因子(VEGF)是一种重要的靶点, 血管生成,靶向这一途径的药物已被用于治疗卵巢癌和其他癌症。临床 然而,使用抗VEGF治疗仅在无进展或总体上产生了适度的改善, 卵巢癌患者的生存率,可能是由于肿瘤微环境的适应性变化。那里 仍然需要开发增强抗VEGF疗法的功效和阻断生长的方法, 促进适应性变化。抗VEGF治疗的适应性耐药机制主要是 未知了解抗VEGF治疗的适应性耐药性有可能显着 增强抗VEGF治疗在卵巢癌患者中的疗效。我们的初步发现表明, 肿瘤相关巨噬细胞(TAM)和髓源性抑制细胞(MDSC)基本上 增加抗VEGF治疗耐药肿瘤和TAM消耗(与CSF 1 R抑制剂)可以改善 抗VEGF治疗的有效性;然而,发生这种情况的机制尚不清楚, 明白在这个建议中,我们将探讨巨噬细胞有助于适应性免疫的机制。 抗VEGF治疗的抗性,并测试VEGF和TAM/MDSC的双重靶向的功效。我们 中心假设是靶向微环境中的TAM将逆转免疫表型, 通过贝伐单抗诱导的改变和改善临床疗效。我们将进行一个新的,归纳, 一项随机补充临床研究,旨在评估添加CSF 1 R抑制剂对识别和 通过客观缓解和无事件生存率衡量,克服这些影响。拟议的工作是 在卵巢癌中,VEGF是高度翻译的,并且具有显著增强抗VEGF治疗的功效的潜力。 癌症患者。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANIL K SOOD其他文献

ANIL K SOOD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANIL K SOOD', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10709228
  • 财政年份:
    2023
  • 资助金额:
    $ 34.45万
  • 项目类别:
Targeting EGFL6 in Ovarian Cancer
靶向 EGFL6 治疗卵巢癌
  • 批准号:
    10709231
  • 财政年份:
    2023
  • 资助金额:
    $ 34.45万
  • 项目类别:
Harnessing the power of exosomes for non-coding RNA delivery
利用外泌体的力量进行非编码 RNA 递送
  • 批准号:
    9754614
  • 财政年份:
    2017
  • 资助金额:
    $ 34.45万
  • 项目类别:
Harnessing the power of exosomes for non-coding RNA delivery
利用外泌体的力量进行非编码 RNA 递送
  • 批准号:
    9979631
  • 财政年份:
    2017
  • 资助金额:
    $ 34.45万
  • 项目类别:
Developmental Research Program
发展研究计划
  • 批准号:
    10251119
  • 财政年份:
    2017
  • 资助金额:
    $ 34.45万
  • 项目类别:
Harnessing the power of exosomes for non-coding RNA delivery
利用外泌体的力量进行非编码 RNA 递送
  • 批准号:
    9388779
  • 财政年份:
    2017
  • 资助金额:
    $ 34.45万
  • 项目类别:
Harnessing the power of exosomes for non-coding RNA delivery
利用外泌体的力量进行非编码 RNA 递送
  • 批准号:
    10670211
  • 财政年份:
    2017
  • 资助金额:
    $ 34.45万
  • 项目类别:
Project 3: The Role of Macrophages in Resistance to Anti-VEGF Drugs in Ovarian Cancer
项目3:巨噬细胞在卵巢癌抗VEGF药物耐药中的作用
  • 批准号:
    10005297
  • 财政年份:
    2017
  • 资助金额:
    $ 34.45万
  • 项目类别:
Career Enhancement Program
职业提升计划
  • 批准号:
    10005302
  • 财政年份:
    2017
  • 资助金额:
    $ 34.45万
  • 项目类别:
Career Enhancement Program
职业提升计划
  • 批准号:
    10251120
  • 财政年份:
    2017
  • 资助金额:
    $ 34.45万
  • 项目类别:

相似海外基金

ICF: AbVax Combination vaccination and broadly neutralising antibody therapy in HIV to induce a protective Tcell vaccinal effect, a mechanistic study
ICF:AbVax 联合疫苗接种和广泛中和 HIV 抗体疗法诱导保护性 T 细胞疫苗效应,一项机制研究
  • 批准号:
    MR/Y008847/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.45万
  • 项目类别:
    Research Grant
Development of CD81 Antibody Therapy for Osteosarcoma - Focused on Exosomes -
骨肉瘤 CD81 抗体疗法的开发 - 专注于外泌体 -
  • 批准号:
    23K08593
  • 财政年份:
    2023
  • 资助金额:
    $ 34.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus
IN-002 的 GMP 生产和 IND 备案,这是一种针对呼吸道合胞病毒的有效吸入粘液捕获抗体疗法
  • 批准号:
    10761398
  • 财政年份:
    2023
  • 资助金额:
    $ 34.45万
  • 项目类别:
SBIR Phase I: Antibody Therapy that Targets Neoantigens in Acute Myeloid Leukemia via the Antibody Dependent Cell-mediated Cytotoxicity Mechanism of Natural Killer Cells
SBIR 第一期:通过抗体依赖性细胞介导的自然杀伤细胞的细胞毒性机制,针对急性髓性白血病新抗原的抗体疗法
  • 批准号:
    2246487
  • 财政年份:
    2023
  • 资助金额:
    $ 34.45万
  • 项目类别:
    Standard Grant
Precise Modulation of Immunometabolism to Boost Antibody Therapy in Oral Cancer
精确调节免疫代谢以促进口腔癌的抗体治疗
  • 批准号:
    10511223
  • 财政年份:
    2022
  • 资助金额:
    $ 34.45万
  • 项目类别:
Precise Modulation of Immunometabolism to Boost Antibody Therapy in Oral Cancer
精确调节免疫代谢以促进口腔癌的抗体治疗
  • 批准号:
    10643886
  • 财政年份:
    2022
  • 资助金额:
    $ 34.45万
  • 项目类别:
Re-designing anti-CD20 monoclonal antibody therapy using novel insights into limitations of innate immune cytotoxicity
利用对先天免疫细胞毒性局限性的新见解重新设计抗 CD20 单克隆抗体疗法
  • 批准号:
    10511323
  • 财政年份:
    2022
  • 资助金额:
    $ 34.45万
  • 项目类别:
Re-designing anti-CD20 monoclonal antibody therapy using novel insights into limitations of innate immune cytotoxicity
利用对先天免疫细胞毒性局限性的新见解重新设计抗 CD20 单克隆抗体疗法
  • 批准号:
    10657706
  • 财政年份:
    2022
  • 资助金额:
    $ 34.45万
  • 项目类别:
Hacking Co-Stimulatory Receptors with Targeted Checkpoint Antibody Therapy
用靶向检查点抗体疗法攻击共刺激受体
  • 批准号:
    574961-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 34.45万
  • 项目类别:
    University Undergraduate Student Research Awards
Imaging the multifaceted response to a bispecific antibody therapy
双特异性抗体疗法的多方面反应成像
  • 批准号:
    10451574
  • 财政年份:
    2021
  • 资助金额:
    $ 34.45万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了